At Solid IO, we are transforming oncology and immunotherapy with next-generation organ-on-chip technology powered by advanced bioengineering and AI. Our patient-specific tumor models provide real-time, biologically relevant insights that help oncologists, researchers, and pharmaceutical innovators make precise, informed treatment decisions.
By replicating the tumor microenvironment and combining it with computational intelligence, our platform eliminates uncertainty, accelerates drug development, optimizes clinical trials, and expands access to advanced cancer therapies.
With Solid IO, the next era of precision oncology begins now.
➡️ Advancing immuno-oncology research
➡️ Bridging science, bioengineering & clinical application
➡️ Optimizing drug development & patient outcomes with AI-supported insights
WHY SOLID IO?
✅ Real-time patient-specific insights — Predict treatment responses before and during therapy.
✅ Faster, more efficient drug development — Reduce trial timelines and optimize biomarker validation.
✅ Transforming immuno-oncology — Unlock next-gen personalized immunotherapies.
✅ Powered by advanced bioengineering & AI — Turning biological complexity into actionable decisions.
✅ Scalable, global impact — Making precision oncology more accessible & clinically relevant.
Bringing precision to where it matters most — real-world patient care.
WHO WE WORK WITH
• Cancer Clinics & Research Centers — Advance breakthrough trials & personalized treatment pathways.
• Pharmaceutical & Biotech Companies — Accelerate drug R&D, patient stratification, and regulatory approvals.
• Investors & Partners — Drive global expansion and impact in precision medicine.
We are seeking visionary partners to push the boundaries of precision oncology.
Let’s collaborate to redefine cancer care.
Visit our website: www.solid-io.com
Partner with us: noora.hujala@solid-io.com
Based in Helsinki, Finland | Collaborating Globally
